wpe44.jpg (19083 bytes)

Contact  Abortion   Influenza   Smallpox  Polio  Vitamin K Hepatitis   Cervical Cancer/HPV   Mercury  Pharma  PANDAS  DTaP  MMR   Chickenpox  Meiningitis Ingredients  Package Inserts  Pediatrics   Conflict of Interest  Population Control  Bible  New Shots  Science of Destruction Shaken Baby Syndrome  2008-2009 waiver/exemption

 

Conference Calls  

 

Neurosurgeon, Dr. Russell Blaylock, shares the science on how particular vaccine ingredients lead to convulsions, seizures, ADD, ADHD, autism...etc.

Be sure to subscribe in order to get in on the free conference calls.    You will receive alerts for the dates of every upcoming call with the topic description and the access  number to dial.

Your Name:
Your Email Address:                    

 

wpe4C3.jpg (4992 bytes)

wpe39.jpg (6951 bytes)

 

wpe3C.jpg (6056 bytes)

 

wpe4F8.jpg (5439 bytes)

 

wpe4.jpg (3184 bytes)

 

wpe51B.jpg (9266 bytes)

wpe50E.jpg (9616 bytes)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Do Vaccines Work-Meningitis

Meningococcal meningitis (also known as aseptic meningitis) is an infection caused by the bacterium Neisseria meningitidis (also known as meningococcus) that causes inflammation of the membranes (meninges) that cover the brain, brain stem, and spinal cord and are caused by bacterial or viral infections.

Only 5%-20% of the population has the menigococcus bacteria.  Infections are very rare.  Especially that of the C strain that is targeted by the vaccine. 

Viral meningitis is sometimes called aseptic meningitis to indicate it is not the result of bacterial infection and cannot be treated with antibiotics.   Symptoms of meningitis, which may appear suddenly, often include high fever, severe and persistent headache, stiff neck, nausea, and vomiting. Changes in behavior such as confusion, sleepiness, and difficulty waking up may also occur. In infants, symptoms of meningitis may include irritability or fatigue, lack of appetite, and fever. Viral meningitis usually resolves in 10 days or less, but other types of meningitis can be deadly if not treated promptly. Anyone experiencing symptoms of meningitis or encephalitis should see a doctor immediately.

There are three meningitis pathogens targeted by vaccination:  Hemophilus influenzae, Pneumococcal meningitis , and Meningitis due to N. meningitidis.  None of which have been scientifically proven safe or effective.

wpeE.jpg (3866 bytes)

Hemophilus Infuenzae is said to be the most common form of bacterial meningitis in the USA targeted by the hemophilus influenzae type b vaccination.  The term "Hib disease" does not necessarily mean "meningitis".  It is used for any disease where the Hib is found through laboratory testing.  It is not defined by symptoms but the lab results only.  The clinical definition is unclear.

HiB Finland 01a.wmf (15024 bytes)There are eight biotypes in all but the vaccine only has one.   Hemophilus Influenzae type b supposedly accounts for 95% of the hemophilus Influenzae diseases in children and 50% of the hemophilus influenzae diseases in adults.   These strains cause mucosal infections, including otitis media, conjunctivitis, sinusitis, bronchitis, and pneumonia.  The frequency of Hib infections in patients with asplenia, splenectomy, sickle cell disease, malignancies, and congenital or acquired immunodeficiencies is higher than in individuals without these conditions. Most strains (80%) colonize in the nasopharynx behind the nose. 

Transmission is acquired by inhalation of respiratory tract droplets that can be sneezed, coughed up and simply breathed out by the infected.  The incubation period is unknown.    Before vaccinations the hemophilus disease was uncommon only found in 2-5% of children.  The incidence rate in the USA is 0.00% at approximately 1 in every 1, 042, 145.  The CDC's numbers are 260 average cases annually and 625 deaths from hemophilus infuenzae annually.  For a 300 million population, that's only 2%.  Is that enough to merit the a mass vaccination?  

 

hib-pittsburgh 0-4 1994.jpg (164248 bytes)In 1987, Minnesota state epidemiologist, Michael Osterhom reported that the vaccine was actually increasing Hib infections instead of decreasing them.  To the NIH he reported that in a study the Hib vaccine showed a five fold increase.  The study showed the vaccine inability to "prevent" infection by -86%.  Yes, that's negative 86%.

In a 2000 publication from CDC cites a 25% increase in insulin dependent diabetes in vaccine recipients receiving Hib vaccinations.  This during a study done in Finland.   (Data from New Zealand and Italy showed a 50% increase from the Hepatitis b vaccination).  CDC's data showed that a child vaccinated after two months of life had an even greater risk of developing diabetes at 60%.

 

 

 

HiB UK 01a.WMF (21260 bytes)One of the Australian vaccine information sheets specifically states that brain damage can occur.   These can later manifest in behavioral, developmental and neurological disorders.   Some have experienced so much regression that they are unresponsive.  This sounds very similar to symptoms of autism. 

CDC suspected failure in 1993 when 30-50 cases are reported after adequate vaccination.  Failure of the vaccine had already been established in a 1992 publication of the American Family Physician.

The vaccine, though invented and "recommended" to target meningitis,  is not measured for success in disease elimination but Hib bacteria are found in laboratory tests.

Children are less likely to develop natural immunity from being exposed to vaccinated children

wpeE.jpg (3866 bytes)

There are two vaccines used to supposedly fight against the Pneumococcal meningitis for which there are over 90 serotypes: 

Pnu-Imune 23 (PPV23) - against S. Pneumoniae (primarily for pneumococcal pneumonia) for adults contains 23 serotypes and Prevnar (PCV) - against S. pneumoniae (primarily for pneumococcal meningitis) used on infants contains 7 serotypes.   Scientists, in a New England Journal of Medicine 2000 article, concluded that bacterial meningitis in the USA is primarily in adults, not in small children as previously stated.  Like many vaccines, the results of the prelicensure studies of Prevnar were reported and published before they were even complete.  That goes against international rules of reporting clinical trials. 

The foundation of the trials was to establish merit in vaccinating newborns with the vaccine.  However, the 38,000 infants used in the trial were not included in NEJM publication supporting the idea.  Did something go wrong that would have led to suspicion against it's claims of efficacy for small infants?   Another factor in the studies, which were conducted by both Wyeth and Kaiser Permanente, is that the children were also given the more reactive DPT vaccination instead of the DTaP known to bring on less adverse reactions.  In doing so, they put these children in even greater risk for traumatically serious adverse reactions during the course of five years.  The two companies were given write off privileges for such reactions as seizures, high fevers, irritability....etc as having anything to do with the Prevnar.  With the simple stroke of their pens, they were allowed to dismiss such reactions as having anything to do with the Prevnar and then blamed it all on the reactive DPT vaccination.  Where's the science in that?

The Prevnar is a four shots series at $60/shot and only cover 7 of the serotypes.  The big price tag insures big profits for the manufacturer.  In 2000 there were only 1,500 reported cases of pneumococcal meningitis among infants.  In comparative average of 3 million (at the least) babies born in America every year, that is not even a 1% case rate for the year.  That's less than one percent at 0.0005%.  However, with the marketed argument passed down to Pediatricians from CDC and on to parents being ear infections, profits for this unmerited vaccine are guaranteed. Prevnar is hailed as the vaccine to reduce and/or prevent ear infections.  However, when it was licensed, that is not what it was necessarily licensed for use against.  In Pre-licensure studies the vaccine was found to decrease ear infections by only 6% as compared to the unvaccinated population.  The case of preventing ear infections with the Prevnar vaccine is also on shaky ground after licensure.  60% of ear infections are actually viral.  Less than 40% are bacterial and only 25% of ear infections may have anything to do with the pneumococcus.   So, over 60% of ear infections are unaffected by antibiotics.  Dr. Van Heerbeek, in a 2006 Reuters publication, confirms the vaccines inability to prevent or reduce ear infections.

Indeed there are some ethical issues that need to be addressed in the trial of Prevnar.  Many of the doctors involved in the testing and approval process have conflict of interests.  Safety testing was inadequate.   Of the chronic and debilitating disease seen in the vaccine, studies were only conducted for 5 years. 

In a Dallas investigative report, Dr. Erdem Cantekin quotes "It is an ineffective and toxic vaccine" and that "the alleged benefits of this new vaccine are greatly exaggerated and the risks are significant."  Soon after it's license in the U.S. there were 117 deaths reported shortly after vaccination. 

Mother Nature Fights Back 

A September 2007 publication points out the unfortunate effect of the Prevnar vaccine causing the drug resistant dominance of a bacteria not included in Prevnar.  "The best way to prevent these resistant infections from spreading is to be careful about how we use antibiotics," said Dr. Cynthia Whitney, chief of respiratory diseases at the federal Centers for Disease Control and Prevention.  The 19A strain has been resistant to all pediatric medication.   While some of the infected children had to undergo surgery for tubes to help drain the infections, others were subjected to a strong antibiotic not yet tested for safety in children.  21,000 of 19A bacterial samples have been tested in the USA and are becoming a great concern as they increase.  From 4% in the three previous years, between 2005-2006 there was a 15% increase amongst children 2 years old and under.   The 19A was also found to be in 40% of cases resistant to medical treatment.   35% were found to be resistant to penicillin between 2004-2005.  The year before Prevnar vaccine was licensed and recommended there was only 2% of them to be resistant to penicillin.  Because these bacteria easily swap gene components to become even more hardy, "new types may emerge that can both escape containment by vaccine and spread throughout the world," says Dr. Daniel Musher of Baylor College of Medicine wrote in the New England Journal of Medicine. 

wpe1C2.jpg (17916 bytes)October of 2007 yet another "super bug" has been identified and given the name MRSA for methicillin-resistant Staphylococcus aureus.  MRSA is a strain of the ubiquitous bacterium that usually causes staph infections that are easily treated with common, or first-line, antibiotics in the penicillin family, such as methicillin and amoxicillin. Resistant strains of the organism, however, have been increasingly turning up in hospitals and in small outbreaks outside of heath-care settings, such as among athletes, prison inmates and children. MRSA, which is spread by casual contact, rapidly turns minor abscesses and other skin infections into serious health problems, including painful, disfiguring "necrotizing" abscesses that eat away tissue. The infections can often still be treated by lancing and draining sores and quickly administering other antibiotics, such as bactrim. But in some cases the microbe gets into the lungs, causing unusually serious pneumonia, or spreads into bone, vital organs and the bloodstream, triggering life-threatening complications. Those patients must be hospitalized and given intensive care, including intravenous antibiotics such as vancomycin. For the year 2005 researches calculated that MRSA strikes over 31 out of every 100,000 Americans.  With a population of 300 million that equals to a disturbing number of over 930,000 Americans infected and 18,000 MRSA associated deaths.  In paper, Michael E. Pichichero and Janet R. Casey of  The University of Rochester, NY document another growing strain of Streptococcus pneumoniae.  Researchers attributed this to the vaccine (Prevnar) used against ear infections. "The use of the vaccine created an ecological vacuum, and that combined with excessive use of antibiotics to create this new superbug," Pichichero said.  America, we most definitely have a problem.

"The most frequent type of drug- resistant skin infections among people going to emergency rooms is about three times more prevalent than U.S. health officials thought, according to new research. There were 31.8 cases of methicillin-resistant Staphylococcus aureus, or MRSA, for every 100,000 persons in the U.S. in 2005... All of the children in the study were vaccinated with Prevnar (pneumococcal vaccine) . The researchers found that the strains not included in the Prevnar vaccine were becoming more numerous and more resistant to standard antibiotics. "

On the VAERS database the Prevnar vaccine has been associated with over 217 deaths since 2000.  One example is that of 9 month old Hayley Graves who developed seizures 40 hours after her second dose that the hospital staff couldn't stop.   For the next 45 days she slipped in and out of a coma before she breathed her last breath.  However, this is not old news.  While the question still remains as to whether the vaccine is the direct cause of those deaths listed on the VAERS database, it is still unexplained.   In it's prelicensure study against an experimental meningitis vaccine, Prevnar was associated with 12 deaths while the experimental Meningococcal group C conjugate vaccine [MnCC])    vaccine in the controlled group was associated with 21 deaths.   Also in the study, Prevnar was found to increase seizures by 4%.  Yet the FDA and CDC dismissed the seizures as having anything to do with the vaccinations.

 The Prevnar vaccines shows failure almost immediately in the USA. The Minnesota State Health Department  admits that infections after vaccination should be expected.   You read it right.  They refused to go into the number of cases amongst the vaccinated children they had experienced.  In 2004 JAMA published the failure of the vaccine submitted to the VAERS database for the years 2000-2002.  In those two years there were 4,154 reports of adverse reactions associated with Prevnar.  The database had submissions of 23 positive rechallenges and 34 cases of invasive pneumococcal infections.  They confirmed the submission of 117 deaths as well.  there were 393 seizure with 94 of them being febrile seizures.

The World Health Organization admits in 2008 that the Pneumococcal Conjugate Vaccine (PCV) is completely useless in preventing pneumonia.   Therefore it doesn't justify the cost the government is putting out for it.   It was found that incidents of asthma is doubled by the vaccine.  The typical reaction of the manufacturer (Wyeth) is that the Indian article contains innacurate and misleading statements.

 

wpeE.jpg (3866 bytes)

wpe356.jpg (27129 bytes)The efficacy study for Menactra (with 4 serotypes)  against Meningitis due to N. meningitidis was compared with the efficacy of Menomune (with 4 serotypes).  The Menomune brought on a greater response in antibody production.  While the manufacturer's product insert   for Menactra states that the vaccine has not been tested for it's immune response for individuals with compromised immune systems, the CDC recommends it's use on such individuals.  No indication is given on the package insert for safety studies conducted on those with compromised immune systems and Menactra.  Another caution put out by the manufacturer is the use of th vaccine on pregnant mothers.  CDC simply makes a move of negligence and assumes safety of the vaccine, anyway, for pregnant mothers.  

There were 6 clinical studies for Menactra with 7,642 participants 11-55 years old who received the Menactra and only 3,041 that received the Menomune vaccine.  One must remember that it is all together difficult to obtain accurate comparative safety analysis with such a difference in participation numbers between the two groups.  Once again, these studies did not include a group with an inert substance such as a saline solution.   The lack thereof makes it even more difficult to achieve accurate comparative analysis on the safety of vaccines.

The most commonly reported adverse reactions were local pain, headache and fatigue.  Most of these reactions were after the administration of Menactra.  The number of severity was also higher after the use of Menactra.  Guillain-Barre was reported after the administration of Menactra during the studies.  The FDA put out an the alert September 30, 2005 on 5 GB cases.  The CDC and FDA reported a total of 15 cases of Guillain-Barre in vaccine recipients of the Menactra in October.  The FDA also admitted that "Also, vaccine adverse events are not always reported to FDA so there may be additional cases of which we are unaware at this time."

There have been over 1,160 reports of adverse reactions after Menactra vaccination.

wpeE.jpg (3866 bytes)

ANOTHER ONE BITES THE DUST

Vaccination against Meningococcal infections can now be added to the long list of vaccine failures.   Britain was the first European country to introduce the vaccine against meningitis.   In 2000, after a year of vaccinations, cover ups are uncovered in Britain.   There were over 16,000 serious adverse reactions reported.  (The Ministry of Health admits that only 10-15% reactions are ever reported).  Despite the eleven deaths experienced by vaccinated individuals, the MOH insisted that the vaccine was safe.   Britain's Justice Awareness Basic Support Group received daily calls of children with serious reactions.  Thus, the government assurance of safety was on seriously shaky ground.  Dr. Jayne Donegan witnessed an increase of serious reactions and testified to the government branding of vaccine refusal amongst parents as an act of irresponsibility. 

The Australian government publishes several in 2005.  In one case a three year old was vaccinated with Menjugate months prior to his diagnosis.   His 16 month old sibling had also been vaccinated four months prior.  Four days later his 7 year old sibling (who had not been vaccinated) developed symptoms and was hospitalized and treated.  They were given the same disease diagnosis.  Nine days later the 9 year old sibling also developed symptoms and was hospitalized.  The Monjugate is no exception when it comes to serious adverse reactions.  50% of infants receiving the vaccine will become irritable.  Other symptoms include nausea, vomiting, minor skin rashes, dizziness and tiredness and some may faint at the time of the injection.    Infants also experienced high pitched crying during the trials.   

wpe4A5.jpg (8718 bytes)With the use of the MeNZB vaccine in New Zealand, the Ministry of Health declares vaccine failure after the death of a fully vaccinated 2 year old in 2006.  According to the Ministry of Health, their published research shows that less than 13% of older infants have "protected levels of antibodies within 7 months of the third vaccine dose.   Despite this information, they insist on a 4th dose for infants.  So, the third dose does nothing to give prevention (doesn't work).  Obviously, had the 1st and second doses brought on "protective levels" the third dose would not have been suggested or recommended.  All this to equal vaccine failure.   The following day the Ministry of Health discloses more deaths that took place after vaccination with the same vaccine.   Only this time it comes out the MeNZB vaccine is a " medical experiment on one million healthy New Zealand children".  Between 2005 and 2006 there are 4 published deaths after vaccination in New Zealand.  The following stats that clearly indicate an already decline prior to vaccination in New Zealand were provided with the New Zealand article.  More cases of infection despite vaccination have been published.

The United Kingdom witness an increase of meningitis related deaths after the introduction of the Meningitis C vaccine by about 17%.  In 2000 the London Obersever publishes 11 deaths said to be blamed on the same vaccine.  The government was accused of covering up the safety issues of the vaccine. 

10% or more of vaccine recipients experience "Crying (infants), irritability, sleepiness, change in eating habits, diarrhea and vomiting (toddlers), and headache, myalgia, and arthralgia in adults" according to the product insert.  Seizures have also been reported. Irritability is in 50% of vaccinated infants. The safety studies were compared with another vaccine, MenBvac, which was supposedly more reactive.   No Efficacy trials have been performed with MeNZB so there is 0% guarantee that it will either work.  This should explain it's failures in New Zealand.

wpe230.jpg (54480 bytes)

Failure continues into 2007.  The New Zealand medical officer was disappointed to see the vaccine failure continue. So if the mass experimentation continues, should this be considered an efficacy trial gone down?  Logically speaking, of course.

Previous Page  Conclusion

wpeE.jpg (3866 bytes)

web stats